<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01442064</url>
  </required_header>
  <id_info>
    <org_study_id>FVF3426g (Cohort 2)</org_study_id>
    <nct_id>NCT01442064</nct_id>
  </id_info>
  <brief_title>An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)</brief_title>
  <official_title>An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) or Macular Edema Secondary to Retinal Vein Occlusion (RVO) Who Have Completed a Genentech-Sponsored Ranibizumab Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genentech, Inc.</source>
  <brief_summary>
    <textblock>
      This is an open-label, multicenter, extension study of intravitreally administered
      ranibizumab in two cohorts. The first cohort (reported separately under FVF3426g,
      NCT00379795) enrolled subjects with primary or recurrent Choroidal Neovascularization (CNV)
      secondary to Age-Related Macular Degeneration (AMD) who completed the treatment phase of a
      Genentech sponsored study (FVF2598g (NCT00056836), FVF2587g (NCT00061594), or FVF2428g
      (NCT00056823)). The second cohort (reported here) enrolled subjects with macular edema
      secondary to Retinal Vein Occlusion (RVO) who completed the 6-month treatment and 6-month
      observation phases (12 months total) of a Genentech sponsored study (FVF4165g (NCT00486018)
      or FVF4166g (NCT00485836)). Patients were enrolled within 14 days of completion of the
      previous study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Ocular Adverse Events in the Study Eye</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Non-ocular Adverse Events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Additional information about adverse events can be found in the adverse events section.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline (Day 0 of extension study), Months 6, 12, 18, and 24</time_frame>
    <description>Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Central Foveal Thickness at Month 6 and Month 12</measure>
    <time_frame>Baseline (Day 0 of extension study), Months 6 and 12</time_frame>
    <description>Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)</measure>
    <time_frame>Baseline (Day 0 of extension study), Months 12 and 24</time_frame>
    <description>NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24.
Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">608</enrollment>
  <condition>Macular Edema</condition>
  <condition>Retinal Vein Occlusion</condition>
  <arm_group>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranibizumab 0.5 mg</intervention_name>
    <description>Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).</description>
    <arm_group_label>Ranibizumab 0.5 mg</arm_group_label>
    <other_name>Lucentis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  The 6-month treatment and 6-month observation phases (12 months total) of a
             Genentech-sponsored ranibizumab study for RVO (FVF4165g or FVF4166g)

          -  Expectation by the investigator that the subject may potentially benefit from
             intravitreal anti-vascular endothelial growth factor (VEGF) treatment

        Exclusion Criteria:

          -  History of intraocular surgery (including cataract extraction, scleral buckle, etc.)
             within 1 month prior to Day 0 of this extension study

          -  Concurrent use of systemic anti-VEGF agents

          -  Use of RVO treatments not approved by the Food and Drug Administration (FDA) in the
             study eye

          -  Use of intravitreal bevacizumab in the study eye and/or fellow eye

          -  Macular edema in the study eye due to other causes than RVO such as diabetes

          -  History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the
             study eye

          -  History of idiopathic or autoimmune-associated uveitis in either eye

          -  Uncontrolled glaucoma in the study eye (defined as intraocular pressure â‰¥ 30 mmHg
             despite treatment with antiglaucoma medication)

          -  Pregnancy or lactation

          -  Premenopausal women not using adequate contraception

          -  History of other disease, metabolic dysfunction, physical examination finding, or
             clinical laboratory finding giving reasonable suspicion of a disease or condition that
             contraindicates the use an investigational drug or that might affect interpretation of
             the results of the study or render the subject at high risk for treatment
             complications

          -  Current treatment for active systemic infection

          -  Inability to comply with study or follow-up procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Lai, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Genentech, Inc.</affiliation>
  </overall_official>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 26, 2011</study_first_submitted>
  <study_first_submitted_qc>September 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2011</study_first_posted>
  <results_first_submitted>December 5, 2011</results_first_submitted>
  <results_first_submitted_qc>December 5, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 10, 2012</results_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CNV</keyword>
  <keyword>Lucentis</keyword>
  <keyword>AMD</keyword>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>RVO</keyword>
  <keyword>Macular edema secondary to retinal vein occlusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Edema</mesh_term>
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is an open label multi-center extension study for participants who completed FVF4165g BRAVO (NCT00486018) or FVF4166g CRUISE (NCT0048583). Cohort 2 consists of enrolled participants with macular edema secondary to retinal vein occlusion (RVO).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranibizumab (Sham BRAVO)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
        </group>
        <group group_id="P2">
          <title>Ranibizumab (0.3 mg BRAVO)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
        </group>
        <group group_id="P3">
          <title>Ranibizumab (0.5 mg BRAVO)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
        </group>
        <group group_id="P4">
          <title>Ranibizumab (Sham CRUISE)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
        </group>
        <group group_id="P5">
          <title>Ranibizumab (0.3 mg CRUISE)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
        </group>
        <group group_id="P6">
          <title>Ranibizumab (0.5 mg CRUISE)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="107"/>
                <participants group_id="P6" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Ranibizumab-Treated Subjects</title>
              <participants_list>
                <participants group_id="P1" count="93">Includes participants who received Ranibizumab in either the initial studies or the extension study.</participants>
                <participants group_id="P2" count="103"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="96"/>
                <participants group_id="P5" count="107"/>
                <participants group_id="P6" count="99"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug in Extension Study</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="60"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="89"/>
                <participants group_id="P6" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="101"/>
                <participants group_id="P3" count="104"/>
                <participants group_id="P4" count="98"/>
                <participants group_id="P5" count="106"/>
                <participants group_id="P6" count="99"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor decision</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="88"/>
                <participants group_id="P3" count="92"/>
                <participants group_id="P4" count="88"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="87"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition mandated other intervention</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranibizumab (Sham BRAVO)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
        </group>
        <group group_id="B2">
          <title>Ranibizumab (0.3 mg BRAVO)</title>
          <description>In this extension study participant received Ranibizumab 0.5 mg intravitreal injection administered as needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
        </group>
        <group group_id="B3">
          <title>Ranibizumab (0.5 mg BRAVO)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
        </group>
        <group group_id="B4">
          <title>Ranibizumab (Sham CRUISE)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
        </group>
        <group group_id="B5">
          <title>Ranibizumab (0.3 mg CRUISE)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
        </group>
        <group group_id="B6">
          <title>Ranibizumab (0.5 mg CRUISE)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="103"/>
            <count group_id="B3" value="104"/>
            <count group_id="B4" value="98"/>
            <count group_id="B5" value="107"/>
            <count group_id="B6" value="99"/>
            <count group_id="B7" value="608"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45 to &lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="38"/>
                    <measurement group_id="B4" value="37"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 to &lt;85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="49"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="59"/>
                    <measurement group_id="B7" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>â‰¥85 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="52"/>
                    <measurement group_id="B6" value="39"/>
                    <measurement group_id="B7" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="55"/>
                    <measurement group_id="B6" value="60"/>
                    <measurement group_id="B7" value="330"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Ocular Adverse Events in the Study Eye</title>
        <description>Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>Ranibizumab- Treated Participants includes all participants who received Ranibizumab in one of the initial studies or this extension study. This analysis includes only those adverse events that occurred during this extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab (Sham BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab (0.3 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (0.5 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab (Sham CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received sham intravitreal injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
          </group>
          <group group_id="O5">
            <title>Ranibizumab (0.3 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
          <group group_id="O6">
            <title>Ranibizumab (0.5 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibuzumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Ocular Adverse Events in the Study Eye</title>
          <description>Number of participants with: any ocular adverse events, ocular adverse events causing treatment discontinuation, ocular serious adverse events, intraocular inflammation and cataracts that occurred in the study eye.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.</description>
          <population>Ranibizumab- Treated Participants includes all participants who received Ranibizumab in one of the initial studies or this extension study. This analysis includes only those adverse events that occurred during this extension study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any ocular adverse event (AE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="63"/>
                    <measurement group_id="O4" value="60"/>
                    <measurement group_id="O5" value="67"/>
                    <measurement group_id="O6" value="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular AE leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ocular serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="10"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intraocular inflammation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cataract</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Non-ocular Adverse Events</title>
        <description>Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Additional information about adverse events can be found in the adverse events section.</description>
        <time_frame>Up to 24 months</time_frame>
        <population>Ranibizumab- Treated Participants includes all participants who received Ranibizumab in one of the initial studies or this extension study. This analysis includes only those adverse events that occurred during this extension study.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab (Sham BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab (0.3 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (0.5 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab (Sham CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received sham intravitreal injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
          </group>
          <group group_id="O5">
            <title>Ranibizumab (0.3 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
          <group group_id="O6">
            <title>Ranibizumab (0.5 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibuzumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Non-ocular Adverse Events</title>
          <description>Number of participants with non-ocular adverse events (not occurring in the eye) in the following categories: any adverse events, serious adverse events, adverse events leading to study discontinuation and death.
Only adverse events that occurred during this extension study are reported. For subjects in the crossover groups who started their first ranibizumab injection in this extension study, adverse events that occurred prior to any ranibizumab injection were also excluded.
Additional information about adverse events can be found in the adverse events section.</description>
          <population>Ranibizumab- Treated Participants includes all participants who received Ranibizumab in one of the initial studies or this extension study. This analysis includes only those adverse events that occurred during this extension study.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="96"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any non-ocular adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="58"/>
                    <measurement group_id="O5" value="71"/>
                    <measurement group_id="O6" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious non-ocular adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="21"/>
                    <measurement group_id="O6" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-ocular adverse event led to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the Best Corrected Visual Acuity (BCVA)</title>
        <description>Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
        <time_frame>Baseline (Day 0 of extension study), Months 6, 12, 18, and 24</time_frame>
        <population>Enrolled participants for whom data was available for analyses at the given time-points. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab (Sham BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab (0.3 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (0.5 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab (Sham CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received sham intravitreal injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
          </group>
          <group group_id="O5">
            <title>Ranibizumab (0.3 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
          <group group_id="O6">
            <title>Ranibizumab (0.5 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibuzumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Best Corrected Visual Acuity (BCVA)</title>
          <description>Change from baseline in then BCVA was assessed by the number of letters a patient could read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) Eye Chart at a Starting Test Distance of 4 Meters. An increase in the number of letters read indicates improvement in visual acuity.</description>
          <population>Enrolled participants for whom data was available for analyses at the given time-points. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
          <units>letters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=88,96,98,90,101,91)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="8.1"/>
                    <measurement group_id="O2" value="-2.2" spread="10.5"/>
                    <measurement group_id="O3" value="-1.3" spread="7.1"/>
                    <measurement group_id="O4" value="-3.2" spread="10.4"/>
                    <measurement group_id="O5" value="-4.1" spread="10.7"/>
                    <measurement group_id="O6" value="-3.2" spread="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=66,66,73,58,69,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="6.9"/>
                    <measurement group_id="O2" value="-2.3" spread="11.5"/>
                    <measurement group_id="O3" value="-0.7" spread="7.3"/>
                    <measurement group_id="O4" value="-4.2" spread="11.3"/>
                    <measurement group_id="O5" value="-5.2" spread="13.8"/>
                    <measurement group_id="O6" value="-4.1" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 18 (n=23,26,32,31,26,22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="5.0"/>
                    <measurement group_id="O2" value="-1.7" spread="6.3"/>
                    <measurement group_id="O3" value="-6.1" spread="15.5"/>
                    <measurement group_id="O4" value="-5.1" spread="14.6"/>
                    <measurement group_id="O5" value="-6.1" spread="12.1"/>
                    <measurement group_id="O6" value="-0.8" spread="10.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=0,2,0,0,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with data available for this time point.</measurement>
                    <measurement group_id="O2" value="-4.5" spread="16.3"/>
                    <measurement group_id="O3" value="NA">No participants with data available for this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants with data available for this time point.</measurement>
                    <measurement group_id="O5" value="-1.0">Only 1 participant in this group. Standard deviation not calculated.</measurement>
                    <measurement group_id="O6" value="NA">No participants with data available for this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Central Foveal Thickness at Month 6 and Month 12</title>
        <description>Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.</description>
        <time_frame>Baseline (Day 0 of extension study), Months 6 and 12</time_frame>
        <population>Enrolled participants for whom data was available for analyses at the given time-point as indicated by &quot;n&quot; in the categories. Observed data were used with no imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab (Sham BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab (0.3 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (0.5 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab (Sham CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received sham intravitreal injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
          </group>
          <group group_id="O5">
            <title>Ranibizumab (0.3 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
          <group group_id="O6">
            <title>Ranibizumab (0.5 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibuzumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Central Foveal Thickness at Month 6 and Month 12</title>
          <description>Change from baseline in Central foveal (retinal) thickness was assessed by Optical Coherence Tomography (OCT). OCT was conducted at the study sites by personnel who were certified by the University of Wisconsin Fundus Photograph Reading Center.</description>
          <population>Enrolled participants for whom data was available for analyses at the given time-point as indicated by &quot;n&quot; in the categories. Observed data were used with no imputation.</population>
          <units>Âµm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6 (n=86,96,97,90,101,89)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.5" spread="131.6"/>
                    <measurement group_id="O2" value="36.8" spread="159.8"/>
                    <measurement group_id="O3" value="40.2" spread="117.4"/>
                    <measurement group_id="O4" value="87.4" spread="217.1"/>
                    <measurement group_id="O5" value="161.4" spread="289.1"/>
                    <measurement group_id="O6" value="94.6" spread="235.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (n=62,65,72,56,69,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="124.9"/>
                    <measurement group_id="O2" value="6.3" spread="163.7"/>
                    <measurement group_id="O3" value="35.3" spread="110.6"/>
                    <measurement group_id="O4" value="79.7" spread="199.4"/>
                    <measurement group_id="O5" value="88.3" spread="262.9"/>
                    <measurement group_id="O6" value="68.4" spread="252.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)</title>
        <description>NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24.
Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).</description>
        <time_frame>Baseline (Day 0 of extension study), Months 12 and 24</time_frame>
        <population>Enrolled participants for whom data was available for analyses at the given time-points. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranibizumab (Sham BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO and received ranibizumab in the 6 month observation period of BRAVO or in this extension study.</description>
          </group>
          <group group_id="O2">
            <title>Ranibizumab (0.3 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O3">
            <title>Ranibizumab (0.5 mg BRAVO)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO.</description>
          </group>
          <group group_id="O4">
            <title>Ranibizumab (Sham CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year)for 24 months. Participants in this group received sham intravitreal injections in the 6 month treatment period of CRUISE and received ranibizumab in the 6 month observation period of CRUISE or in this extension study.</description>
          </group>
          <group group_id="O5">
            <title>Ranibizumab (0.3 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
          <group group_id="O6">
            <title>Ranibizumab (0.5 mg CRUISE)</title>
            <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection as-needed administered no more frequently than every 30 days (no more than 12 injections per year) for 24 months. Participants in this group received 0.5 mg Ranibuzumab intravitreal injections in the 6 month treatment period of CRUISE.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Visual Function Composite Score, as Measured by the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25)</title>
          <description>NEI VFQ-25 is a 25 item questionnaire that assesses visual function and quality of life for a total possible score of 0 to 100. A higher score represents better functioning. The change from baseline is calculated at Month 12 and Month 24.
Participants are grouped according to the treatment they received in initial studies FVF4165g BRAVO (NCT00486018) and FVF4166g CRUISE (NCT00485836).</description>
          <population>Enrolled participants for whom data was available for analyses at the given time-points. Observed data were used with no imputation. The number of participants for whom data was available for analyses is represented by &quot;n&quot;.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="103"/>
                <count group_id="O3" value="104"/>
                <count group_id="O4" value="98"/>
                <count group_id="O5" value="107"/>
                <count group_id="O6" value="99"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12 (n=64,65,72,58,67,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="10.0"/>
                    <measurement group_id="O2" value="-0.7" spread="9.7"/>
                    <measurement group_id="O3" value="-0.7" spread="8.6"/>
                    <measurement group_id="O4" value="0.1" spread="10.5"/>
                    <measurement group_id="O5" value="-1.0" spread="8.0"/>
                    <measurement group_id="O6" value="-1.6" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24 (n=0,2,0,0,1,0)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">No participants with data available for this time point.</measurement>
                    <measurement group_id="O2" value="6.2" spread="7.4"/>
                    <measurement group_id="O3" value="NA">No participants with data available for this time point.</measurement>
                    <measurement group_id="O4" value="NA">No participants with data available for this time point.</measurement>
                    <measurement group_id="O5" value="-13.3">Only 1 participant with data available in this group. Standard deviation not calculated.</measurement>
                    <measurement group_id="O6" value="NA">No participants with data available for this time point.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 24 months</time_frame>
      <desc>Safety Population included all participants who received at least one dose of study drug in one of the initial studies or this extension study. These analyses include only those adverse events that occurred during this extension study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ranibizumab (Sham)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received intravitreal sham injections in the 6 month treatment period of BRAVO or the 6 month treatment period of CRUISE and received Ranibizumab during the 6 month observation period of the initial study or this extension study.</description>
        </group>
        <group group_id="E2">
          <title>Ranibizumab (0.3 mg)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.3 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO or the 6 month treatment period of CRUISE.</description>
        </group>
        <group group_id="E3">
          <title>Ranibizumab (0.5 mg)</title>
          <description>In this extension study participants received Ranibizumab 0.5 mg intravitreal injection administered as-needed no more frequently than every 30 days (no more than 12 injections per year) up to 24 months. Participants in this group received 0.5 mg Ranibizumab intravitreal injections in the 6 month treatment period of BRAVO or the 6 month treatment period of CRUISE.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>COR PULMONALE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>AMAUROSIS FUGAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CYSTOID MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>MACULAR ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>OPTIC ISCHAEMIC NEUROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RETINAL VEIN OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED TRANSIENTLY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>VITREOUS HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>COLITIS ISCHAEMIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>INTESTINAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>LOWER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>BACTERIAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ENDOPHTHALMITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PAROTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION PSEUDOMONAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>JOINT DISLOCATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTRAOCULAR PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS INADEQUATE CONTROL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ROTATOR CUFF SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SPINAL OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SYNOVIAL CYST</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA PANCREAS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>LUNG CARCINOMA CELL TYPE UNSPECIFIED STAGE IV</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>LYMPHOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>METASTATIC NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA METASTATIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>T-CELL PROLYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>AUTONOMIC NERVOUS SYSTEM IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PRESYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>TESTICULAR PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ANGIOEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ARTERIAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ARTERIOSCLEROSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>LABILE HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="179" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="172" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CONJUNCTIVAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>CYSTOID MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>EYE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>MACULAR OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>MACULOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RETINAL DEPIGMENTATION</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RETINAL EXUDATES</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RETINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>RETINAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>VISUAL ACUITY REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>VITREOUS DETACHMENT</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="203"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>INTRAOCULAR PRESSURE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="210"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="203"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Genentech</name_or_title>
      <organization>Genentech</organization>
      <email>ctg-post-d@gene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

